Contributions
Abstract: S106
Type: Oral Presentation
Presentation during EHA22: On Friday, June 23, 2017 from 11:45 - 12:00
Location: Hall B
Background
Polatuzumab vedotin (pola) is an antibody drug conjugate containing the anti-mitotic MMAE targeting CD79b, an antigen expressed ubiquitously in DLBCL. Pola as monotherapy and in combination with anti-CD20 antibodies demonstrated encouraging efficacy in r/r DLBCL.1,2 The initial dose-escalation portion of this multicenter, open-label Ph Ib/II study of pola in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) showed an acceptable safety profile and established a recommended Ph II dose of pola at 1.8 mg/kg.3 We report updated safety and efficacy results for the Ph II dose in 45 previously untreated DLBCL patients (pts) (ClinicalTrials.gov NCT01992653).
Aims
To evaluate the safety and efficacy of pola-R-CHP as first-line treatment in patients with DLBCL.
Methods
Five pts of the dose escalation phase and the 40 pts of the expansion phase were included in this analysis. All pts provided informed consent to participate in the study. All had newly diagnosed DLBCL and were treated with pola at 1.8 mg/kg and R-CHP at standard doses every 21 days for 6 or 8 cycles. Investigator assessments for anti-tumor activity were performed according to IWG 2007 following 4 cycles and at the end of study treatment (EOT).
Results
All 45 pts received at least one dose of study drug. The median age was 69 years; 93% were >60 years, 33% ECOG >1, 82% Stage III/IV, and 78% IPI 3-5. Of the 29 pts with cell of origin (COO) status by digital gene expression, 11 (38%) were ABC, 14 (48%) were GCB, while 4 (14%) were unclassified.
Conclusion
Session topic: 20. Aggressive Non-Hodgkin lymphoma - Clinical
Keyword(s): Targeted therapy, Phase II, DLBCL, Antibody targeting
Abstract: S106
Type: Oral Presentation
Presentation during EHA22: On Friday, June 23, 2017 from 11:45 - 12:00
Location: Hall B
Background
Polatuzumab vedotin (pola) is an antibody drug conjugate containing the anti-mitotic MMAE targeting CD79b, an antigen expressed ubiquitously in DLBCL. Pola as monotherapy and in combination with anti-CD20 antibodies demonstrated encouraging efficacy in r/r DLBCL.1,2 The initial dose-escalation portion of this multicenter, open-label Ph Ib/II study of pola in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) showed an acceptable safety profile and established a recommended Ph II dose of pola at 1.8 mg/kg.3 We report updated safety and efficacy results for the Ph II dose in 45 previously untreated DLBCL patients (pts) (ClinicalTrials.gov NCT01992653).
Aims
To evaluate the safety and efficacy of pola-R-CHP as first-line treatment in patients with DLBCL.
Methods
Five pts of the dose escalation phase and the 40 pts of the expansion phase were included in this analysis. All pts provided informed consent to participate in the study. All had newly diagnosed DLBCL and were treated with pola at 1.8 mg/kg and R-CHP at standard doses every 21 days for 6 or 8 cycles. Investigator assessments for anti-tumor activity were performed according to IWG 2007 following 4 cycles and at the end of study treatment (EOT).
Results
All 45 pts received at least one dose of study drug. The median age was 69 years; 93% were >60 years, 33% ECOG >1, 82% Stage III/IV, and 78% IPI 3-5. Of the 29 pts with cell of origin (COO) status by digital gene expression, 11 (38%) were ABC, 14 (48%) were GCB, while 4 (14%) were unclassified.
Conclusion
Session topic: 20. Aggressive Non-Hodgkin lymphoma - Clinical
Keyword(s): Targeted therapy, Phase II, DLBCL, Antibody targeting